account
Baxter Healthcare Corp., a subsidiary of medical device maker Baxter International Inc. (BAX ) has initiated a phase III clinical trial to evaluate Gammagard Liquid, marketed as Kiovig in European Union, for the treatment of mild-to-moderate Alzheimer's disease.
Gammagard is an immunoglobulin replacement
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
This article has:
- 27 views
- 1 save
Reactions to Baxter Healthcare initiates phase III study to evaluate Gammagard Liquid for Alzheimer's
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account